Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

被引：0
|
作者：
Akira Sawaki
Yasuhide Yamada
Yoshito Komatsu
Tatsuo Kanda
Toshihiko Doi
Masato Koseki
Hideo Baba
Yu-Nien Sun
Koji Murakami
Toshirou Nishida
机构：
[1] Aichi Cancer Center Hospital,Department of Gastroenterology
[2] National Cancer Center Hospital,Gastrointestinal Oncology Division
[3] Hokkaido University Hospital,Department of Gastroenterology
[4] Niigata University Hospital,Digestive and General Surgery 2 Division
[5] National Cancer Center Hospital East,Division of Gastrointestinal Oncology
[6] National Hospital Organization Kure Medical Center,Department of Surgery
[7] Kumamoto University Hospital,Department of Surgical Pathology
[8] Amgen Inc.,Department of Pharmacokinetics and Drug Metabolism
[9] Dokkyo University School of Medicine,PET Center
[10] Osaka University Hospital,Department of Digestive Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 65卷
关键词：
Motesanib; Angiogenesis inhibitor; Gastrointestinal stromal tumor (GIST);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：961 / 967
页数：6
相关论文
共 50 条
  • [41] A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib
    Wagner, A. J.
    Yazji, S.
    Morgan, J. A.
    Choy, E.
    George, S.
    Hohos, M.
    O'Mara, M.
    Demetri, G. D.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [42] Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors
    Fujisaka, Yasuhito
    Yamada, Yasuhide
    Yamamoto, Noboru
    Shimizu, Toshio
    Fujiwara, Yutaka
    Yamada, Kazuhiko
    Tamura, Tomohide
    Watanabe, Hiroyuki
    Sun, Yu-Nien
    Bass, Michael B.
    Seki, Mitsuo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (05) : 935 - 943
  • [43] Does imatinib mesylate (IM) affect longterm outcome in patients with gastrointestinal stromal tumors (GISTs)?
    Jin, Judy
    Robinson, Ann
    Willis, Joseph
    Hardacre, Jeffrey
    Kim, Julian
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 205 (03) : S14 - S14
  • [44] Necrotizing granulomatous disease in patients receiving imatinib mesylate treatment for gastrointestinal stromal tumors (GIST)
    Brueckl, V
    Agaimy, A.
    Ullrich, E.
    Krieg, S.
    Stegmann, A.
    Mackensen, A.
    Meidenbauer, N.
    ONKOLOGIE, 2011, 34 : 252 - 252
  • [45] Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors
    Seshadri, Ramakrishnan A.
    Rajendranath, Rejiv
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2009, 5 (04) : 267 - 271
  • [46] Necrotizing granulomatous disease in patients receiving imatinib mesylate treatment for gastrointestinal stromal tumors (GIST)
    Meidenbauer, N.
    Stegmann, A.
    Mackensen, A.
    Agaimy, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Is there a role for surgery in patients with "unresectable" cKIT plus gastrointestinal stromal tumors treated with imatinib mesylate?
    Scaife, CL
    Hunt, KK
    Patel, SR
    Benjamin, RS
    Burgess, MA
    Chen, LL
    Trent, J
    Raymond, AK
    Cormier, JN
    Pisters, PWT
    Pollock, RE
    Feig, BW
    AMERICAN JOURNAL OF SURGERY, 2003, 186 (06): : 665 - 669
  • [48] Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment
    Yeh, Chun-Nan
    Chen, Tsung-Wen
    Liu, Feng-Yuan
    Jan, Yi-Yin
    Chen, Miin-Fu
    LANGENBECKS ARCHIVES OF SURGERY, 2006, 391 (06) : 615 - 621
  • [49] Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST)
    D'Ambrosio, L.
    Ponzetti, A.
    Lista, P.
    Bombaci, S.
    Palesandro, E.
    Galizia, D.
    Aliberti, S.
    Allione, P.
    Manca, A.
    Gallo, S.
    Grignani, G.
    Aglietta, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
    Vincenzi, Bruno
    Nannini, Margherita
    Badalamenti, Giuseppe
    Grignani, Giovanni
    Fumagalli, Elena
    Gasperoni, Silvia
    D'Ambrosio, Lorenzo
    Incorvaia, Lorena
    Stellato, Marco
    Ceruso, Mariella Spalato
    Napolitano, Andrea
    Valeri, Sergio
    Santini, Daniele
    Tonini, Giuseppe
    Casali, Paolo Giovanni
    Dei Tos, Angelo Paolo
    Pantaleo, Maria Abbondanza
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
12345